UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/450/0.1/15.01.25 | Market Closed - BOERSE MUENCHEN 03:40:56 2024-05-31 pm EDT | ||
| 4.71 EUR | +16.30% |
|
| 1 month | +117.05% | ||
| 3 months | +11.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 4.71 | +16.30% |
| 24-05-30 | 4.05 | +1.00% |
| 24-05-29 | 4.01 | -5.42% |
| 24-05-28 | 4.24 | -12.94% |
| 24-05-27 | 4.87 | +1.88% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 03:40 pm EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC49Q1 |
| ISIN | DE000HC49Q12 |
| Date issued | 2023-02-20 |
| Strike | 450 $ |
| Maturity | 2025-01-15 (228 Days) |
| Parity | 10 : 1 |
| Emission price | 1.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.24 € |
|---|---|
| Lowest since issue | 1.36 € |
| Spread | 0.03 € |
| Spread % | 0.63% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Warrants
- Warrant
